Two Contradictory Fates Following a Similar Malignancy: Is Prognosis Predictable in Borderline Ovarian Tumors?

Document Type : Case Report

Authors

1 Professor, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Borderline ovarian tumors make a small contribution to the ovarian pathologies; however, with regard to the prevalence of this malignancy at reproductive age, prognosis and standard treatment of these patients are of great significance in oncology trials. The present study aimed to introduce two patients with borderline ovarian tumors to examine the prognosis determinants based on similar studies.Case Report: In the winter of 2018, two patients with similar medical history of ovarian cysts diagnosed in 2016 with stage I epithelial ovarian tumor (borderline) pathology referred to an emergency department in a university hospital. The first patient was a 29-year-old woman. Following the surgery to preserve her fertility, the mentioned patient experienced relapse and metastases without any proper responses to treatment. Despite all the efforts of the medical team, the patient died due to the severity of her disease. The other patient was a 26-year-old woman, who was admitted at 36th week of pregnancy with the diagnosis of preeclampsia, and delivered a 2800-gram healthy boy.Conclusion: Although it seems that borderline tumor is distinct from other ovarian malignancies in term of prognosis, based on the present case report, the prognosis must be investigated in each patient in individualize manner.

Keywords

References

  1. Seong SJ, Kim DH, Kim MK, Song T. Controversies in borderline ovarian tumors. J Gynecol Oncol 2015; 26(4): 343-9.
  2. Martin M, Grisham RN, Turashvili G, Halpenny DF, Aghajanian CA, Makker V. Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation. Gynecol Oncol Rep 2017; 22: 9-12.
  3. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, et al. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol 2011; 120(3): 480-4.
  4. Comert DK, Ureyen I, Karalok A, Tasci T, Turkmen O, Ocalan R, et al. Mucinous borderline ovarian tumors: Analysis of 75 patients from a single center. J Turk Ger Gynecol Assoc 2016; 17(2): 96-100.
  5. Chen X, Fang C, Zhu T, Zhang P, Yu A, Wang S. Identification of factors that impact recurrence in patients with borderline ovarian tumors. J Ovarian Res 2017; 10(1): 23.
  6. Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 2010; 21(1): 55-60.
  7. Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO. Interventions for the treatment of borderline ovarian tumours. Cochrane Database Syst Rev 2010; (9): CD007696.
  8. Sutton GP, Bundy BN, Omura GA, Yordan EL, Beecham JB, Bonfiglio T. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991; 41(3): 230-3.
  9. Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004; 100(5): 1045-52.
  10. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 2012; 118(12): 3087-94.
  11. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2003; 83 Suppl 1: 135-66.
  12. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol 2011; 123(3): 511-6.
  13. Smith Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: A clinicopathologic analysis of 135 cases. Am J Surg Pathol 2003; 27(6): 725-36.
  14. Patrono MG, Minig L, Diaz-Padilla I, Romero N, Rodriguez Moreno JF, Garcia-Donas J. Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment. Ecancermedicalscience 2013; 7: 379.
  15. Lalwani N, Shanbhogue AK, Vikram R, Nagar A, Jagirdar J, Prasad SR. Current update on borderline ovarian neoplasms. AJR Am J Roentgenol 2010; 194(2): 330-6.
  16. Fortin A, Morice P, Thoury A, Camatte S, Dhainaut C, Madelenat P. Impact of infertility drugs after treatment of borderline ovarian tumors: Results of a retrospective multicenter study. Fertil Steril 2007; 87(3): 591-6.
  17. Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013; 119(3): 548-54.
  18. du Bois A, Ewald-Riegler N, du Bois O, Harter P. Borderline-Tumoren des Ovars-eine systematische ubersicht. Geburtshilfe Frauenheilkde 2009; 69(09): 807-33.
Journal of Isfahan Medical School
Volume 37, Issue 525 - Serial Number 525
March and April 2019
Pages 475-479

Files

History

  • Receive Date: 01 May 2019
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics